Evidence map›Paper›PMID 35379190›Full record

ArticleBMC infectious diseases2022

Regional opening strategies with commuter testing and containment of new SARS-CoV-2 variants in Germany.

Martin J Kühn, Daniel Abele, Sebastian Binder, Kathrin Rack, Margrit Klitz, Jan Kleinert, Jonas Gilg, Luca Spataro, Wadim Koslow, Martin Siggel and 2 more

Abstract read
In one paragraph

Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Martin J KühnInstitute for Software Technology, German Aerospace Center, Cologne, Germany. Martin.Kuehn@DLR.de.
Daniel AbeleInstitute for Software Technology, German Aerospace Center, Cologne, Germany.
Sebastian BinderDepartment of Systems Immunology and Braunschweig Integrated Centre of Systems Biology (BRICS), Helmholtz Centre for Infection Research, Braunschweig, Germany. SB@Theoretical-Biology.de.
Kathrin RackInstitute for Software Technology, German Aerospace Center, Cologne, Germany.
Margrit KlitzInstitute for Software Technology, German Aerospace Center, Cologne, Germany.
Jan KleinertInstitute for Software Technology, German Aerospace Center, Cologne, Germany.
Jonas GilgInstitute for Software Technology, German Aerospace Center, Cologne, Germany.
Luca SpataroInstitute for Software Technology, German Aerospace Center, Cologne, Germany.
Wadim KoslowInstitute for Software Technology, German Aerospace Center, Cologne, Germany.
Martin SiggelInstitute for Software Technology, German Aerospace Center, Cologne, Germany.
Michael Meyer-HermannDepartment of Systems Immunology and Braunschweig Integrated Centre of Systems Biology (BRICS), Helmholtz Centre for Infection Research, Braunschweig, Germany. MMH@Theoretical-Biology.de.
Achim BasermannInstitute for Software Technology, German Aerospace Center, Cologne, Germany. Achim.Basermann@DLR.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite the vaccination process in Germany, a large share of the population is still susceptible to SARS-CoV-2. In addition, we face the spread of novel variants. Until we overcome the pandemic, reasonable mitigation and opening strategies are crucial to balance public health and economic interests.

methodsWe model the spread of SARS-CoV-2 over the German counties by a graph-SIR-type, metapopulation model with particular focus on commuter testing. We account for political interventions by varying contact reduction values in private and public locations such as homes, schools, workplaces, and other. We consider different levels of lockdown strictness, commuter testing strategies, or the delay of intervention implementation. We conduct numerical simulations to assess the effectiveness of the different intervention strategies after one month. The virus dynamics in the regions (German counties) are initialized randomly with incidences between 75 and 150 weekly new cases per 100,000 inhabitants (red zones) or below (green zones) and consider 25 different initial scenarios of randomly distributed red zones (between 2 and 20% of all counties). To account for uncertainty, we consider an ensemble set of 500 Monte Carlo runs for each scenario.

resultsWe find that the strength of the lockdown in regions with out of control virus dynamics is most important to avoid the spread into neighboring regions. With very strict lockdowns in red zones, commuter testing rates of twice a week can substantially contribute to the safety of adjacent regions. In contrast, the negative effect of less strict interventions can be overcome by high commuter testing rates. A further key contributor is the potential delay of the intervention implementation. In order to keep the spread of the virus under control, strict regional lockdowns with minimum delay and commuter testing of at least twice a week are advisable. If less strict interventions are in favor, substantially increased testing rates are needed to avoid overall higher infection dynamics.

conclusionsOur results indicate that local containment of outbreaks and maintenance of low overall incidence is possible even in densely populated and highly connected regions such as Germany or Western Europe. While we demonstrate this on data from Germany, similar patterns of mobility likely exist in many countries and our results are, hence, generalizable to a certain extent.

Indexed as

COVID-19SARS-CoV-2Communicable Disease ControlGermanyHumansCovid-19Mitigation strategyModelingNoCovid strategyNonpharmaceutical interventionPredictive analyticsSARS-CoV-2

Identifiers

PMID35379190
PMCPMC8978163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.